Charles R. Cantor

Boston University

Primary Section: 29, Biophysics and Computational Biology
Secondary Section: 41, Medical Genetics, Hematology, and Oncology
Membership Type: Member (elected 1988)


After more than 40 years in academia holding positions in chemistry and human genetics & development at Columbia University, molecular biology at U. California Berkeley, and biomedical engineering and pharmacology at Boston University I switched to the private sector where I cofounded Sequenom the company that first commercialized non invasive prenatal testing , and Retrotope, a clinical stage pharmaceutical company using deuterated essential nutrients as drugs.

Research Interests

I am assisting about 20 biotechnology companies as a director, adviser, or consultant. Many focus on technologies targets or novel approaches to liquid biopsies. Others are employing artificial intelligence for improved diagnostics or therapies. Still other companies are developing very rapid diagnostic methods. Finally I work with companies developing novel therapeutic modalities.

Powered by Blackbaud
nonprofit software